Claim Amendments

Please enter the following amendments, which consist of the cancellation of claims 12, 13, 21 and 23-25.

1 (original): A method of treating a mammal having type 1 diabetes or at risk for type 1 diabetes, the method comprising administering to the mammal a pharmaceutical composition comprising an agent that inhibits a macrophage migration inhibitory factor (MIF) in the mammal, wherein the agent is a polypeptide or a polynucleotide.

2 (original): The method of claim 1, wherein the agent comprises a binding site of an antibody that binds specifically to the MIF.

3 (original): The method of claim 2, wherein the agent is an antibody.

4 (original): The method of claim 1, wherein the agent is an aptamer that binds specifically to the MIF.

5 (original): The method of claim 1, wherein the agent inhibits expression of the MIF.

6 (original): The method of claim 5, wherein the agent is an antisense nucleic acid or mimetic specific for MIF mRNA in the mammal.

7 (original): The method of claim 5, wherein the agent is a ribozyme nucleic acid or mimetic specific for MIF mRNA in the mammal.

8 (original): The method of claim 5, wherein the agent is an inhibitory RNA or mimetic specific for MIF mRNA in the mammal.

9 (original): The method of claim 1, wherein the mammal has or is at risk for having diabetes, impaired glucose intolerance, stress hyperglycemia, metabolic syndrome, and/or insulin resistance.

10 (original): The method of claim 1, wherein the mammal is a rodent.

11 (original): The method of claim 1, wherein the mammal is a human.

12-13 (canceled)

14 (original): A method of evaluating whether a compound is useful for preventing or treating type 1 diabetes, the method comprising

(a) determining whether the compound inhibits a macrophage migration inhibitory factor (MIF) in a mammal, then, if the compound inhibits the MIF,

(b) determining whether the compound inhibits development of type 1 diabetes.

15 (original): The method of claim 14, wherein step (b) is performed by evaluating the effect of the compound on proliferation of splenic lymphocytes in the mammal.

16 (original): The method of claim 14, wherein the compound is a protein.

17 (original): The method of claim 16, wherein the protein comprises an antibody binding site.

18 (original): The method of claim 14, wherein the compound is a nucleic acid or mimetic.

19 (original): The method of claim 18, wherein the nucleic acid or mimetic is an antisense, a ribozyme, an aptamer, or an interfering RNA.

20 (original): The method of claim 14, wherein the compound is an organic molecule less than 1000 Dalton.

21 (canceled)

22 (original): A kit comprising

(a) a pharmaceutical composition comprising the agent used to inhibit MIF in claim 1, and

(b) instructions for administering the composition to the mammal,

wherein the mammal has type 1 diabetes or is at risk for type 1 diabetes.

23-25 (canceled)